The Prevention Options for Women Evaluation Research (POWER) Cohort
NCT ID: NCT03490058
Last Updated: 2021-12-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
2255 participants
OBSERVATIONAL
2017-06-14
2021-07-23
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Young women
Sexually active HIV-uninfected women between 16-25 years of age will be given Truvada.
Truvada
A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Truvada
A fixed dose of oral co-formulated tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC) will be used as PrEP.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Able and willing to provide written informed consent
* Recently sexually active (defined as having had vaginal intercourse at least once in the previous three months)
* HIV uninfected based on negative HIV rapid tests, on the date of enrollment
16 Years
25 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Desmond Tutu HIV Foundation
OTHER
Wits Reproductive Health and HIV Institute
OTHER
Kenya Medical Research Institute
OTHER
United States Agency for International Development (USAID)
FED
RTI International
OTHER
Harvard Medical School (HMS and HSDM)
OTHER
University of Pittsburgh
OTHER
National Institute of Mental Health (NIMH)
NIH
University of Washington
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Connie Celum
Prof of Medicine & Global Health, Adjunct Prof of Epidemiology, SOM: Global Health
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Connie L Celum, MD, MPH
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Jared M Baeten, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Washington
Rachel Johnson, MPH
Role: STUDY_DIRECTOR
University of Washington
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kenya Medical Research Institute
Kisumu, , Kenya
Desmond Tutu HIV Foundation
Cape Town, , South Africa
Wits Reproductive Health and HIV Institute
Johannesburg, , South Africa
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Katz AWK, Roberts S, Rousseau E, Khoza MN, Mogaka F, Bukusi E, Delany-Moretlwe S, Bekker LG, Morton JF, Johnson R, Baeten JM, Celum C, van der Straten A. Qualitative Analysis Using Social Maps to Explore Young Women's Experiences With Social Support of their Oral PrEP Use in Kenya and South Africa. J Assoc Nurses AIDS Care. 2023 Jan-Feb 01;34(1):45-57. doi: 10.1097/JNC.0000000000000363. Epub 2022 Sep 23.
Celum CL, Bukusi EA, Bekker LG, Delany-Moretlwe S, Kidoguchi L, Omollo V, Rousseau E, Travill D, Morton JF, Mogaka F, O'Malley G, Barnabee G, van der Straten A, Donnell D, Parikh UM, Kudrick L, Anderson PL, Haberer JE, Wu L, Heffron R, Johnson R, Morrison S, Baeten JM; POWER Study Team. PrEP use and HIV seroconversion rates in adolescent girls and young women from Kenya and South Africa: the POWER demonstration project. J Int AIDS Soc. 2022 Jul;25(7):e25962. doi: 10.1002/jia2.25962.
Roche SD, Barnabee G, Omollo V, Mogaka F, Odoyo J, Bukusi EA, Morton JF, Johnson R, Celum C, Baeten JM, O'Malley G. Implementation strategies for integrating pre-exposure prophylaxis for HIV prevention and family planning services for adolescent girls and young women in Kenya: a qualitative study. BMC Health Serv Res. 2022 Mar 30;22(1):422. doi: 10.1186/s12913-022-07742-8.
Omollo V, Bukusi EA, Kidoguchi L, Mogaka F, Odoyo JB, Celum C, Morton J, Johnson R, Baeten JM. A Pilot Evaluation of Expedited Partner Treatment and Partner Human Immunodeficiency Virus Self-Testing Among Adolescent Girls and Young Women Diagnosed With Chlamydia trachomatis and Neisseria gonorrhoeae in Kisumu, Kenya. Sex Transm Dis. 2021 Oct 1;48(10):766-772. doi: 10.1097/OLQ.0000000000001430.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AID-OAA-A-15-00034
Identifier Type: OTHER_GRANT
Identifier Source: secondary_id
STUDY00000950
Identifier Type: -
Identifier Source: org_study_id